Autism
Clinical Trial Dateline: October 29,
2002 - Abigail Bleck
WINK-TV Ft. Myers :
Researchers are recruiting more than 300 young children ages
2 1/2 to 5 who will receive 6 doses of the drug Secretin or a placebo over a
20 week period.
The FDA recently granted fast-track approval to Secretin because it's said
to improve the social interaction in children with Autism. Earlier studies
reveal that Secretin appears promising and currently researchers at 20
medical facilities across the nation will enroll patients in this phase 3
clinical trial.
"During the study the children will be evaluated before and after treatment
with Secretin using standardized autism diagnostic tools in which we will
focus specifically on changes in social interaction and communication.
During the study, the children will be evaluated by psychologists as well as
their parents," explains Karen Jauregui of Repligen Corportation.
For more information or if you want to enroll your child, call Alachua
Family Psychiatry at 352-333-0094 or Miami's Children's Hospital at
305-663-6802.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.